Synthesis and biological evaluation of pyridazinone analogues as potential cardiac positron emission tomography tracers

Journal of Medicinal Chemistry

Volumn 51, Issue 10, 2008, Pages 2954-2970

  Purohit, Ajay ^a   Radeke, Heike ^a   Azure, Michael ^a   Hanson, Kelley ^a   Benetti, Richard ^b   Su, Fran ^a   Yalamanchili, Padmaja ^c   Yu, Ming ^a   Hayes, Megan ^a   Guaraldi, Mary ^a   Kagan, Mikhail ^a   Robinson, Simon ^a   Casebier, David ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 TERT BUTYL 4 CHLORO 5 (4 (1 FLUORO BUT 2 OXY) BENZYL)OXY 3 (2H) PYRIDAZINONE; 2 TERT BUTYL 4 CHLORO 5 [4 (2 FLUORO D 4 ETHOXY D 2 METHYL) BENZYLOY] 3 (2H) PYRIDAZINONE; 2 TERT BUTYL 4 CHLORO 5 [4 (2 FLUORO ETHOXYMETHYL) BENZYLOXY] 3 (2H) PYRIDAZINONE; 2 TERT BUTYL 4 CHLORO 5 [4 (2 FLUOROPROPOXY)BENZYLOY] 3 (2H) PYRIDAZINONE; 2 TERT BUTYL 4 CHLORO 5 [4 (3 FLUOROBUTYL)BENZYLOXY] 3 (2H) PYRIDAZINONE; 2 TERT BUTYL 4 CHLORO 5 [4 (3 FLUOROPROPOXY)BENZYLOXY] 3 (2H) PYRIDAZINONE; 2 TERT BUTYL 4 CHLORO 5 [4 (4 FLUOROBUTYL)BENZYL] OXY 3 (2H) PYRIDAZINONE; ALKYL GROUP; FLUORINE 18; PYRIDABEN DERIVATIVE; PYRIDAZINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TRACER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; FLUORINATION; HEART; HEART MUSCLE; IC 50; LIVER; LUNG PARENCHYMA; MALE; NONHUMAN; ORGAN DISTRIBUTION; POSITRON EMISSION TOMOGRAPHY; PRIMATE; RAT; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

ANIMALS; CATTLE; ELECTRON TRANSPORT COMPLEX I; FEMALE; FLUORINE RADIOISOTOPES; HEART; MACACA MULATTA; MALE; MITOCHONDRIA, HEART; POSITRON-EMISSION TOMOGRAPHY; PYRIDAZINES; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 43949119789     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701443n     Document Type: Article

References (50)

1. Foot, D. K.; Lewis, R. P.; Pearson, T. A.; Beller, G. A. Demographics and Cardiology 1950-2050. J. Am. Coll. Cardiol. 2000, 35 (5), 66B-80BSuppl. B.
2. Slart, R. H. J. A.; Bax, J. J.; van Veldhuisen, D. J.; van der Wall, E. E.; Dierckx, R. A. J. O. D.; Jager, P. L. Imaging techniques in nuclear cardiology for the assessment of myocardial viability. Int. J. Cardiovasc. Imaging 2006, 22, 63-80.
3. Kapur, A.; Latus, K. A.; Davies, G.; Dhawan, R. T.; Eastick, S.; Jarritt, O. H.; Roussakis, G.; Young, M. C.; Anagnostopoulos, C.; Bomanji, J.; Costa, D. C.; Pennell, D.; J.; Prvulovich, E. M.; Ell, P. J.; Underwood, S. R. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 1608-1616.
4. Koeppe, R. C.; Hutchins, G. D. Instrumentation for Positron Emission Tomography: Tomographs and Data Processing and Display Systems. Semin. Nucl. Med. 1992, 22, 162-181.
5. Herzog, H.; Roesch, F. Chemie und Physik der Bildgebung: PET-und SPECT. Pharm. Unserer Zeit. 2005, 34, 468-473.
6. Cuocolo, A.; Acampa, W.; Imbriaco, M.; DeLuca, N.; Iovino, G. L.; Salvatore, M. The many ways to myocardial perfusion imaging. J. Nucl. Med. Mol. Imaging 2005, 49, 4-18.
7. Beller, G. A. Myocardial perfusion imaging agents: SPECT and PET. J. Nucl. Cardiol. 2004, 11, 71-86.
8. 99mTc-sestamini uptake during adenosine-induced vasodilation as a function of coronary stenosis severity. Circulation 1995, 91, 813-820.
9. Glover, D. K.; Okada, R. D. Myocardial kinetics of Tc-MIBI in canine myocardium after dipyridamole. Circulation 1990, 81, 628-637.
10. Nienaber, C. A. PET in cardiology: current status and clinical expectations. Clin. Physiol. 1994, 14, 337-348.
11. Schwaiger, M. Myocardial Perfusion Imaging with PET. J. Nucl. Med. 1994, 35, 693-698.
12. Von Dahl, J. Untersuchungen der Myokardperfusion mit der Positron-Emissions-Tomographie. Z. Kardiol. 2001, 90, 835-847.
13. Schwaiger, M.; Muzik, O. Assessment of Myocardial Perfusion by Positron Emission Tomography. Am. J. Cardiol. 1991, 67, 35D-43D.
14. Machac, J. Cardiac Positron Emission Tomography Imaging. Semin. Nucl. Med. 2005, 35, 17-36.
15. Talkalkar, A.; Mavi, A.; Alavi, A.; Araujo, L. PET in cardiology. Radiol. Clin. N. Am. 2005, 42, 107-119.
16. Beanlands, R. S. B.; Muzik, O.; Melon, P.; Sutor, R.; Sawada, S.; Muller, D.; Bondie, D.; Hutchins, G. D.; Schwaiger, M. Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13-ammonia positron emission tomography. JACC 1995, 26, 1465-1475.
17. Choi, Y.; Huang, S.-C.; Hawkins, R. A.; Kim, J. Y.; Kim, B.-T.; Hoh, C. K.; Chen, K.; Phelps, M. E.; Schelbert, H. R. Quantification of Myocardial Blood Flow using 13N-Ammonia and PET: Comparison of Tracer Models. J. Nucl. Med. 1999, 40, 1045-1055.
18. Go, R. T.; Marwick, T. H.; MacIntyre, W. J.; Saha, G. B.; Neumann, D. R.; Underwood, D. A.; Simpfendorfer, C. C. A Prospective Comparison of Rubidium-82 PET and Thallium-201 SPECT Myocardial Perfusion Imaging Utilizing a Single Dipyridamole Stress in the Diagnosis of Coronary Artery Disease. J. Nucl. Med. 1990, 31, 1899-1905.
19. Bergmann, S. R.; Herrero, P.; Markham, J.; Weinheimer, C. J.; Walsh, M. N. Noninvasive Quantification of Myocardial Blood Flow in Human Subjects with Oxygen-15-Labeled Water and Positron Emission Tomography. J. Am. Coll. Cardiol. 1989, 14, 639-52.
20. Marshall, R. C.; Powers-Risius, P.; Reutter, B. W.; Taylor, S. E.; VanBrocklin, H. F.; Huesman, R. H.; Budinger, T. F. Kinetic Analysis of [125]I-Iodorotenone as a Deposited Myocardial Flow Tracer: Comparison with [99m]Tc-Sestamibi. J. Nucl. Med. 2001, 42, 272-281.
21. Negherbon, W. O. Handbook of Toxicology. Vol. 111: Insecticides; W. B. Saunders: Philadelphia, 1959; pp 661-673.
22. Tomlin, C. D. S. Rotenone. In The Pesticide Manual, 11th ed.; British Crop Protection Council: Farnham, UK, 1997; 1097-1099.
23. Walker, J. E. The NADH-ubiquinone oxidoreductase (complex I) of respitory chains. Q. Rev. Biophys. 1992, 25, 253-324.
24. Caroll, J.; Fearnley, I. M.; Shannon, R. J.; Hirst, J.; Walker, J. E. Analysis of the subunit composition of complex I from bovine heart mitochondria. Mol. Cell. Proteom. 2003, 2, 117-126.
25. Kronauge, J. F.; Chiu, M. L.; Cone, J. S.; Davidson, A.; Homan, B. L.; Jones, A. G.; Piwnica-Worms, D. Comparison of Neutral and Cationic Myocardial Perfusion Agents: Characteristics of Accumulation in Cultured Cells. Nucl. Med. Biol. 1992, 19, 141-148.
26. Luemmen, P. Complex I inhibitors as insecticides and acaricides. Biochim. Biophys. Acta 1998, 1364, 287-296.
27. Miyoshi, H. Structure-activity relationships of some complex I inhibitors. Biochim. Biophys. Acta 1998, 1364, 236-244.
28. Esposti, M. D. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim. Biophys. Acta 1998, 1364, 222-235.
29. Hollingworth, R. M.; Ahammadsahib, K. I.; Gadelhak, G.; McLaughlin, J. L. New inhibitors of Complex I of the mitochondrial electron transport chain with activity as pesticides. Biochem. Soc. Trans. 1994, 22, 230-233.
30. Lindell, S. D.; Ort, O.; Luemmen, P.; Klein, R. The design and synthesis of novel inhibitors of NADH:ubiquinone oxidoreductase. Bioorg. Med. Chem. Lett. 2004, 14, 511-514.
31. Okun, J. G.; Luemmen, P.; Brandt, U. Three Classes of Inhibitors share a Common Binding Domain in Mitochondrial Complex I (NADH:Ubiquinone Oxidoreductase). J. Biol. Chem. 1999, 274, 2625-2630.
32. Purohit, A.; Benetti, R.; Hayes, M.; Guaraldi, M.; Kagan, M.; Yalamanchili, P.; Su, F.; Azure, M.; Mistry, M.; Yu, M.; Robinson, S.; Dischino, D. D.; Casebier, D. Quinazoline derivatives as MC-I inhibitors: Evaluation of myocardial uptake using positron emission tomography in rat and nonhuman primate. Bioorg. Med. Chem. Lett. 2007, 17, 4882-4885.
33. Radeke, H. S.; Hanson, K.; Yalamanchili, P.; Hayes, M.; Zhang, Z.-Q.; Azure, M.; Yu. M.; Guaraldi, M.; Kagan, M.; Robinson, S.; Casebier, D. Synthesis and Biological Evaluation of Mitochondrial Complex 1 Inhibitor 2-[4-(4-Fluoro-butyl)-benzylsulfanyl]-3-methylchromene-4-one as a Potential Cardiac Positron Emission Tomography Tracer. J. Med. Chem. 2007, 40, 4304-4315.
34. Hirata, K.; Kawamura, Y.; Kudo, M. Development of a New Acaricide, Pyridaben. J. Pestic. Sci. 1995, 20, 177-179.
35. Igarashi, H.; Sakamoto, S. Summary of Toxicity Studies with Pyridaben. J. Pestic. Sci. 1994, 19, S243.
36. 50 > 4000 nM): (Chemical Equation Presented)
37. Degrado, T. R.; Moka, D. C. Non-beta-oxidizable-[18F]fluoro long chain fatty acid analogs show cytochrome P-450-mediated defluorination:implications for the design of PET tracers of myocardial fatty acid utilization. Nucl. Med. Biol. 1992, 19, 389-397.
38. Kilbourn, M. R. Fluorine-18 Labeling of Radiopharmaceuticals; Nuclear Science Series; National Academy Press: Washington, DC, 1990; pp 4470.
39. French, A. N.; Napolitano, E.; Van Brocklin, H. F.; Brodack, J. W.; Hanson, R. N.; Welch, M. J.; Katzenellenbogen, J. A. The β-heteroatom effect in metabolic defluorination: The interaction of resonance and inductive effects may be a fundamental determinant in the metabolic liability of fluorine-substituted compounds. J. Labelled Compd. Radiopharm. 1991, 30, 431-433.
40. Fowler, J. S.; Wang, G.-J.; Logan, J.; Xie, S.; Volkow, N. D.; MacGregor, R. R.; Schyler, D. J.; appas, N.; Alexoff, D. L.; Patlak, C.; Wolf, A. P. Selective Reduction of Radiotracer Trapping by Deuterium Substitution: Comparison of Carbon-11-L-Deprenyl and Carbon-l-Deprenyl-D2 for MAO B Mapping. J. Nucl. Med. 1995, 36, 1255-1262.
41. Shogo, M.; Kazuyoshi, A.; Masuo, Y.; Shuichi, I. Antitumor agent, novel 3(2)-pyridazinone derivatives and their preparation. E.U. Patent 0665 223 A1, January 26, 1995.
42. 2]-(Trifluoromethyl)diazirinyl-pyridaben. J. Labelled Compd. Radiopharm. 1998, 3, 191-199.
43. Suzuki, H.; Kawamura, Y.; Ogura, T. Process for producing 2-tert- butyl-4,5-dichloro-3(2)-pyridazinone. E.U. Patent 0 169 375, June 19, 1985.
44. Lester, R. L.; Smith, A. L. Studies on the electron transport system. 28. The mode of reduction of tetrazolium salts by beef heart mitochondria; role of coenzyme Q and other lipids. Biochim. Biophys. Acta 1961, 47, 475-496.
45. Matsuno-Yagi, A.; Hatefi, Y. Studies on the mechanism of oxidative phosphorylation. Catalytic site cooperativity in ATP synthesis. J. Biol. Chem. 1985, 260, 11424-11427.
46. Satoh, T; Miyoshi, H; Sakamoto, K; Iwamura, H. Comparison of the inhibitory action of synthetic capsaicin analogues with various NADH-ubiquinone oxidoreductases. Biochim. Biophys. Acta 1996, 1273, 21-30.
47. 2A receptors in baboon brain: pharmacological studies. Nucl. Med. Biol 2001, 28, 271-279.
48. 2-5-methoxybenzyl)acetamide: a deuterium-substituted radioligand for peripherial benzodiazepine receptor. Bioorg. Med. Chem. 2006, 13, 1811-1818.
49. Yu, M.; Guaraldi, M. T.; Mistry, M.; Kagan, M.; McDonald, J. L.; Drew, K.; Radeke, H.; Purohit, A.; Azure, M.; Casebier, D. S.; Robinson, S. P. BMS-747158-02: A Novel PET Myocardial Perfusion Imaging Agent. J. Nucl. Cardiol. 2007, 14, 789-796.
50. Yu, M.; Mistry, M.; Guaraldi, M.; Kagan, M.; McDonald, J.; Drew, K.; Hayes, M.; Yalamanchili, P.; Purohit, A.; Radeke, H.; Azure, M.; Hanson, K.; Robinson, S.; Casebier, D. [18F]-RP1012: A Novel Myocardial Perfusion Imaging Agent for Use with Positron Emission Tomography (PET). Circulation 2005, 112 (17), II-761.